New clinical trial data published showing positive results from use of vivos technology to treat obstructive sleep apnea in children

Littleton, colo., june 26, 2025 (globe newswire) -- vivos therapeutics, inc. (“vivos” or the “company”) (nasdaq: vvos), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (osa), today announced that the european journal of pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive results for the treatment of osa in children using vivos' patented daytime-nighttime appliance (dna).
VVOS Ratings Summary
VVOS Quant Ranking